+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Paroxysmal Nocturnal Haemoglobinuria - Pipeline Insight, 2022

  • PDF Icon

    Clinical Trials

  • 80 Pages
  • March 2022
  • Region: Global
  • DelveInsight
  • ID: 4037220
The publisher’s, “Paroxysmal Nocturnal Haemoglobinuria - Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Paroxysmal Nocturnal Haemoglobinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Paroxysmal Nocturnal Haemoglobinuria Understanding

Paroxysmal Nocturnal Haemoglobinuria: Overview

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired, life-threatening disease of the blood. The disease is characterized by complement-mediated hemolysis with or without hemoglobinuria, an increased susceptibility to thrombotic episodes and/or some degree of bone marrow dysfunction. PNH leads to excessive breakdown of red blood cells, leading to the release of a large amount of haemoglobin into the urine. Symptoms and signs of PNH include: fatigue; dark red/brown urine; difficulty swallowing, abdominal pain, infections, and bruising. The principal studies used to establish the diagnosis of PNH are flow cytometry of peripheral blood and bone marrow analysis. PNH typically starts from the early thirties to the mid-forties, and often persisting for decades, with a continued dependence on blood transfusions in a proportion of patients. The appropriate treatment for PNH depends on the severity of symptoms. The mainstay of PNH treatment is the drug eculizumab (Soliris).

'Paroxysmal Nocturnal Haemoglobinuria - Pipeline Insight, 2022' report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Paroxysmal Nocturnal Haemoglobinuria pipeline landscape is provided which includes the disease overview and Paroxysmal Nocturnal Haemoglobinuria treatment guidelines. The assessment part of the report embraces, in depth Paroxysmal Nocturnal Haemoglobinuria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Paroxysmal Nocturnal Haemoglobinuria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Paroxysmal Nocturnal Haemoglobinuria R&D. The therapies under development are focused on novel approaches to treat/improve Paroxysmal Nocturnal Haemoglobinuria.

Paroxysmal Nocturnal Haemoglobinuria Emerging Drugs Chapters

This segment of the Paroxysmal Nocturnal Haemoglobinuria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Paroxysmal Nocturnal Haemoglobinuria Emerging Drugs

Crovalimab: Hoffman-La-Roche

Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using recycling antibody technology. By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit complement activation, which is the cause of a number of diseases. As the complement system is a key innate immune defense mechanism, we plan to study the potential of this antibody in a broader range of complement-mediated diseases. A phase III clinical trial is evaluating crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria.

Pozelimab: Regeneron Pharmaceuticals

Pozelimab is an investigational, fully-human monoclonal antibody designed to block complement factor C5 and prevent the destruction of red blood cells (hemolysis) that cause the symptoms of PNH and other diseases mediated by complement pathway activity. It is an IgG4 antibody that binds with high affinity to wild-type and variant human C5 and blocks its activity. Pozelimab was invented using Regeneron's proprietary VelocImmune technology, which uses a unique genetically-humanized mouse to produce optimized fully-human antibodies. Pozelimab is currently under clinical development, and its safety and efficacy have not been evaluated by any regulatory authority.

Further product details are provided in the report……..

Paroxysmal Nocturnal Haemoglobinuria: Therapeutic Assessment

This segment of the report provides insights about the different Paroxysmal Nocturnal Haemoglobinuria drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Paroxysmal Nocturnal Haemoglobinuria

There are approx. 20+ key companies which are developing the therapies for Paroxysmal Nocturnal Haemoglobinuria. The companies which have their Paroxysmal Nocturnal Haemoglobinuria drug candidates in the most advanced stage, i.e. Phase III include, Hoffman-La-Roche


The publisher’s report covers around 25+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Paroxysmal Nocturnal Haemoglobinuria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Paroxysmal Nocturnal Haemoglobinuria: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Paroxysmal Nocturnal Haemoglobinuria therapeutic drugs key players involved in developing key drugs.

Paroxysmal Nocturnal Haemoglobinuria Report Insights

  • Paroxysmal Nocturnal Haemoglobinuria Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Paroxysmal Nocturnal Haemoglobinuria Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Paroxysmal Nocturnal Haemoglobinuria drugs?
  • How many Paroxysmal Nocturnal Haemoglobinuria drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Paroxysmal Nocturnal Haemoglobinuria?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Paroxysmal Nocturnal Haemoglobinuria therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Paroxysmal Nocturnal Haemoglobinuria and their status?
  • What are the key designations that have been granted to the emerging drugs?

Table of Contents

IntroductionExecutive Summary
Paroxysmal Nocturnal Haemoglobinuria: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)
  • Comparative Analysis

Crovalimab: Hoffman-La-Roche
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Mid Stage Products (Phase II)
  • Comparative Analysis

BCX9930: BioCryst pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Early stage products (Phase I)
  • Comparative Analysis

CAN106: CanBridge
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Inactive Products
  • Comparative Analysis
  • Paroxysmal Nocturnal Haemoglobinuria Key Companies
  • Paroxysmal Nocturnal Haemoglobinuria Key Products
  • Paroxysmal Nocturnal Haemoglobinuria- Unmet Needs
  • Paroxysmal Nocturnal Haemoglobinuria- Market Drivers and Barriers
  • Paroxysmal Nocturnal Haemoglobinuria- Future Perspectives and Conclusion
  • Paroxysmal Nocturnal Haemoglobinuria Analyst Views
  • Paroxysmal Nocturnal Haemoglobinuria Key Companies
  • Appendix

List of Tables
Table 1 Total Products for Paroxysmal Nocturnal Haemoglobinuria
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Paroxysmal Nocturnal Haemoglobinuria
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Hoffmann-La Roche
  • Apellis Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Biocad
  • AKARI Therapeutics
  • Alexion Pharmaceuticals
  • Novartis Pharmaceuticals
  • Amgen
  • BioCryst Pharmaceuticals
  • MorphoSys
  • Ra Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Wuhan Createrna Science and Technology
  • CANbridge
  • Attune Pharmaceuticals
  • RallyBio